Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?

Nature Clinical Practice Oncology volume 2, pages 192–193 (2005)Cite this article

boxed-textMcDermott DF et al. (2005) Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133–141

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Atkins MB et al. (1993) Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11: 661–670

    Article  CAS  Google Scholar 

  2. Yang JC et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127–3132

    Article  CAS  Google Scholar 

  3. Shanafelt AB et al. (2000) A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol 18: 1197–1202

    Article  CAS  Google Scholar 

  4. Shevach EM et al. (2001) Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 182: 58–67

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor in the Departments of Urology and Immunology at Duke University Medical Center, Durham, North Carolina, USA

    Johannes Vieweg

Authors
  1. Johannes Vieweg
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

J Vieweg has received research support from Geron Corporation. He has acted as a consultant for Merix Biosciences, Novartis Pharmaceuticals Corp., and for GlaxoSmithKline. He has an invested interest (options) in Argos Biotherapeutics.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vieweg, J. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?. Nat Rev Clin Oncol 2, 192–193 (2005). https://doi.org/10.1038/ncponc0134

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0134

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing